德国黑措根奥拉赫--(美国商业资讯)--运动品牌PUMA借助Voices of a RE:GENERATION倡议成员、Z世代环保主义者创作的视频和社交媒体内容,让其2024年可持续发展报告更易被年轻受众理解。本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/
伦敦--(美国商业资讯)-- Visa Cash App Racing Bulls一级方程式(Formula One)车队已部署全球领先的工程设计AI平台Neural Concept,通过AI和数据驱动的工程工作流加速车队的赛车设计并优化空气动力学性能,实现更快的设计迭代和更明智的决策。本新闻稿包含多媒
比利时根特、宾夕法尼亚州马尔文和东京--(美国商业资讯)-- H.U. Group Holdings Inc.及其全资子公司Fujirebio今日宣布推出适用于全自动LUMIPULSE G免疫分析系统的Lumipulse G sTREM2检测试剂。该化学发光酶免疫分析(CLEIA)试剂仅限研究用途(RUO),可在短短35
佛罗里达州坦帕--(美国商业资讯)-- BST Global 作为 AEC 行业领先的 AI-powered project intelligence 解决方案提供商,于2025年5月6日至8日在佛罗里达州棕榈滩举办了第二届年度 AI 峰会。本次顶级盛会汇聚了来自全球最具影响力企业的 12 位思想领袖,包括 Ar
Promoting Japanese Makeup Culture Globally and Enhancing Regional PresenceTOKYO--(BUSINESS WIRE)--Kao Corporation (TOKYO:4452) has identified its international makeup brandKATEas a strategic growth driver within its cosmetics
- Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma- ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care
With these satellites, SES is enhancing the O3b mPOWER network to serve customers across multiple market segmentsLUXEMBOURG--(BUSINESS WIRE)--SES announced today that thelatest pair of O3b mPOWER satellites launched in December 202
纽约--(美国商业资讯)--全球性投资者权益律师事务所Rosen Law Firm提醒投资者,一名股东代表在2023年5月8日至2024年5月7日期间购买Treace Medical Concepts, Inc. (NASDAQ: TMCI)证券的投资者提起了集体诉讼。Treace Medical自称是一家专注于提升拇囊炎及相关
BEAVERTON, Ore.--(BUSINESS WIRE)--NIKE, Inc. (NYSE:NKE) announced today that Michael Gonda will become Executive Vice President and Chief Communications Officer of NIKE, Inc., effective July 7, 2025. In this role, Gonda will lead the glo
Assessment based on an in-depth analysis of more than 65 parameters across deployment, operations, and end-of-life disposal of the O3b mPOWER missionLUXEMBOURG--(BUSINESS WIRE)--O3b mPOWER, SESs second-generation medium earth orbi
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary e